The latest on the takeover talks between US health care giant Johnson & Johnson (NYSE: JNJ) and its target Actelion (SIX: ATLN) is that Switzerland’s takeover board has been asked about the viability of a complex deal.
This update has been reported by Swiss newspaper Tages-Anzeiger, which does not quote sources but suggests that the two companies have approached the board, which determines whether a deal meets legal requirements.
The two companies reportedly asked about a proposal under which J&J would acquire Actelion, while separating its commercialized portfolio from its research and development (R&D) assets, a deal structure first reported by the Reuters news agency last week.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze